海角社区

Using cell sorting and a multiomics approach, we are investigating the biology and kinetics of residual leukemia cells treated with a Bruton’s tyrosine kinase inhibitor

_{Relevant publications:}

<sub>Veyhe SR, Hansen MH, Cédile O, Møller MB, Nielsen MK, Thomassen M, Juul-Jensen K, Frederiksen H, Dybkær K, Nyvold CG. Eur J Haematol. 2025

Veyhe SR, Cédile O, Dahlmann SK, Krejcik J, Abildgaard N, Høyer T, Møller MB, Thomassen M, Juul-Jensen K, Frederiksen H, Dybkær K, Hansen MH, Nyvold CG. Int J Mol Sci. 2024</sub>

Profiling of circulating tumor DNA employed in sensitive, longitudinal assessment of treatment response

_{Relevant publications:}

<sub>Vimalathas G, Hansen MH, Cédile O, Thomassen M, Møller MB, Dahlmann SK, Kjeldsen MLG, Hildebrandt MG, Nielsen AL, Naghavi-Behzad M, Edenbrandt L, Nyvold CG, Larsen TS. Blood Adv. 2025

Vimalathas G, Cédile O, Kjeldsen MLG, Thomassen M, Møller MB, Nyvold CG, Hansen MH, Larsen TS. Int J Lab Hematol. 2025

Højlund EL, Cédile O, Larsen TS, Vimalathas G, Møller MB, Hansen MH, Nyvold CG. Int J Lab Hematol. 2023</sub>

Ultra鈥慸eep sequencing of clonal immunoglobulin receptor rearrangements for the assessment of minute levels of residual disease in B cell malignancies.

<sub>Relevant publications:

Hansen MH, Maagaard M, Cédile O, Nyvold CG.MethodsX. 2024.

Cédile O, Hansen MH, Dahlmann SK, Kristensen TK, Abildgaard N, Nyvold CG.Exp Hematol. 2023.

Elkjær LAL, Cédile O, Hansen MH, Nielsen C, Møller MB, Abildgaard N, Haaber J, Nyvold CG.Leuk Res Rep. 2022.

Hansen MH, Cédile O, Larsen TS, Abildgaard N, Nyvold CG.Exp Hematol. 2021.</sub>

This CITCO project focuses on the exhaustive examination of B cell profiles, employing both pre-clinical and clinical approaches to gain deeper insights into the characsteristics of B cell cancers with the focus of finding novel targets to extend the efficact of treatments.

In collaboration with Centre for Cellular Immunotherapy of Haematological Cancer Odense CITCO

Third-generation sequencing is implemented for flexible high-precision clonotyping of malignant B cells and in progressing the field of cytogenomics

_{Relevant publications:}

<sub>Hansen MH, Gulmir R, Cédile O, Dahlmann SK, Veyhe SR, Stougaard M, Juul-Jensen K, Nyvold CG. Eur J Haematol. 2025

Hansen MH, Cédile O, Abildgaard N, Nyvold CG. EJHaem. 2023

Hansen MH, Cédile O, Kjeldsen MLG, Thomassen M, Preiss B, von Neuhoff N, Abildgaard N, Nyvold CG. J Mol Diagn. 2023</sub>

Investigates how MSCs contribute to bone loss and impaired healing in multiple myeloma by uncovering transcriptional and functional MSC alterations

<sub>Relevant publications:

Levring MB, Diaz-delCastillo M, Gundesen MT, Cédile O, Andersen CW, Nielsen AL, Møller HEH, Vinholt PJ, Asmussen JT, Kristensen IB, Nyvold CG, Kassem M, Abildgaard N, Andersen TL, Lund T. Bone. 2025

Johansen M, Levring MB, Stokbro K, Diaz-delCastillo M, Khan AA, Wickstroem LA, Gundesen MT, Kristensen IB, Nyvold CG, Andersen MØ, Andersen TL, Abildgaard N, Lund T. Cancers (Basel). 2023</sub>

Investigates the changes in the T-cell compartment after treatment with engineered antibodies that make T cells recognize and kill the cancer cells

_{Relevant publication:}

_{Krejcik J, Barnkob MB, Nyvold CG, Larsen TS, Barington T, Abildgaard N. Cancers (Basel). 2021}